Over five million Germans suffer from osteoarthritis severe enough to limit daily function. Against chronic joint pain, little has proven effective: glucosamine and chondroitin are now considered ineffective by large clinical trials; pain pills don't solve the problem. A randomized study from the University of Nottingham now points to an unexpected candidate: a daily prebiotic from chicory roots reduced knee pain in six weeks and raised GLP-1 levels in the blood—the same signaling molecule through which the weight-loss drug Ozempic works.
What Inulin Is and Why It Matters Now
Inulin is a plant fiber found in chicory roots, Jerusalem artichokes, garlic, and onions. Human digestive enzymes cannot break it down. Unchanged, it reaches the colon, where gut bacteria ferment it. The key fermentation product is butyrate, a short-chain fatty acid that serves as energy for colon cells, dampens inflammatory signals, and—by newer research—also influences systemic pain processing.
The INSPIRE study is the first randomized controlled trial to investigate this connection in knee osteoarthritis. (INSPIRE stands for lIfestyle iNterventionS for PaIn ReliEf.) Osteoarthritis is the world's most common joint disease. In Germany, approximately 15.4 million people have medically diagnosed osteoarthritis; at least two million experience daily activity limitations from pain.
What the Study Shows
The Nottingham team randomized 136 adults with knee osteoarthritis into four groups: 20 grams of inulin daily, a digital physiotherapy exercise program (PSE), both interventions combined, and a placebo group receiving maltodextrin. After six weeks, data were available from 117 participants.
Inulin reduced pain on the Numerical Rating Scale (0–10) by 1.11 points more than placebo, a moderate effect by standard scientific measurement (Cohen's d = 0.57). Grip strength in the inulin group improved by 4.62 kilograms compared to placebo. Blood concentrations of butyrate (p = 0.025) and GLP-1 (p = 0.011) rose significantly. The study was published in March 2026 in Nutrients (DOI: 10.3390/nu18050714), supported by the Advanced Pain Discovery Platform, the UK Medical Research Council, Versus Arthritis, and the NIHR Nottingham Biomedical Research Centre.
Notably, dropout rates were low: only 3.6 percent of inulin participants withdrew early compared to 21 percent in the physiotherapy group. For most arthritis patients, stirring a daily powder into a drink proved far more practical than a six-week digital exercise program.
GLP-1: A Hormone with Two Faces
GLP-1, glucagon-like peptide-1, is a gut hormone that regulates blood sugar, suppresses appetite, and by recent evidence also influences pain signaling and muscle regeneration. In INSPIRE, higher GLP-1 levels correlated significantly with improved grip strength. The authors call this analysis exploratory—a hint, not proof of a causal mechanism.
GLP-1 is also the mechanism behind semaglutide, the active ingredient in Ozempic and Wegovy. GLP-1 agonists stimulate the same receptor synthetically. That a daily fiber raises GLP-1 naturally and activates similar biochemical pathways was not anticipated with such clarity. Whether this pathway is causally responsible for pain relief remains an open question.
In Comparison: What Previous Supplements Achieved
Glucosamine and chondroitin have been recommended for osteoarthritis for decades and taken by millions. Cochrane reviews consistently conclude they have no clinically meaningful pain effect in knee osteoarthritis. The largest single trial, the US GAIT study with over 1,500 participants, found no statistically significant difference between glucosamine, chondroitin, and placebo on the primary pain endpoint after 24 weeks.
Omega-3 fatty acids have anti-inflammatory properties and show modest effects on joint pain and stiffness in some studies, but haven't entered clinical guidelines for osteoarthritis. Inulin differs conceptually from both: it doesn't act directly in the joint but modulates systemic inflammation and pain pathways through gut bacteria. This is biologically plausible but has barely been clinically tested in osteoarthritis.
Three Gaps Before Clinical Practice
INSPIRE is a first proof of efficacy over six weeks. It is not proof of a standard therapy. Three prerequisites remain unmet.
First: long-term data. Six weeks is too short to know whether pain improvement persists, whether tolerance develops, or whether long-term 20-gram dosing poses risks. Bloating and cramping from high initial inulin doses are typical; the study rated them tolerable.
Second: a larger cohort. 117 participants suffice to show a main effect but not subgroup analyses. Which patients with which microbiome profiles or arthritis severity benefit most remains unclear.
Third: therapeutic standardization. Twenty grams of inulin daily is barely achievable through diet alone. Commercial supplements vary widely in purity, source, and chain length. What exactly needs supplementing is not yet defined. Clinical guidelines will incorporate inulin only after at least one more trial with a longer observation window confirms these results.